ZEISS Unveils AI-Driven Platform for Ophthalmic Research

ZEISS has unveiled a new artificial intelligence-based platform designed to improve ophthalmic research and accelerate the development of personalized treatments for chronic eye diseases. The cloud-based ZEISS Research Data Platform (RDP) aims to streamline research workflows, integrate clinical and research data, and support the creation of data-driven tools for better patient care.

Set to launch in select countries in 2025, the ZEISS RDP enables researchers and clinicians to unify data from a variety of sources, including medical imaging and surgical records. The platform also allows users to develop and train their own algorithms, making use of AI to identify biomarkers and automate complex data analysis.

“The future of healthcare is in the data,” said Euan Thomson, Head of the Digital Business Unit, ZEISS Medical Technology. “The introduction of the ZEISS RDP reflects our commitment to advancing ophthalmic care through smarter, AI-powered tools.”

ZEISS RDP offers secure, user-based access, giving research teams control over their data while supporting collaboration. It is also compatible with existing ZEISS systems such as ZEISS FORUM, reducing the need for manual data transfers and minimizing errors.

The platform's ability to automate processes and centralize diverse datasets is expected to reduce workflow inefficiencies and improve the speed at which research insights are generated. By supporting a transition from siloed research environments to integrated systems, ZEISS aims to help clinicians more easily balance research demands with patient care responsibilities.

In parallel with the new platform, ZEISS is advancing an ongoing collaboration with pharmaceutical company Boehringer Ingelheim. The partnership focuses on the use of AI to support earlier detection and intervention in chronic retinal diseases. By combining ZEISS’ medical ecosystem with Boehringer Ingelheim’s drug development capabilities, the companies are working to create new treatment pathways and improve outcomes for patients at risk of vision loss.

“We are working toward a future in which earlier detection and intervention result in long-term, real-world outcomes that prevent vision loss,” said Heiko G. Niessen, Global Head of Translational Medicine Eye Health, Boehringer Ingelheim.

According to ZEISS, the collaboration highlights a broader strategic goal to enable innovation through partnerships and the use of connected data systems. Both companies see data-driven technologies as key to unlocking new areas of research and advancing personalized care in ophthalmology.